India Glycols has successfully completed its corporate restructuring via an NCLT-sanctioned demerger, effective September 1, 2026. The move splits the company into three focused entities: India Glycols (chemicals), IGL Spirits, and Ennature Bio Pharma. Shareholders will receive shares in the new entities at specified ratios, with listings on BSE and NSE expected to follow. This strategic shift aims to sharpen management focus and optimize capital allocation across segments.
India Glycols Completes Strategic Demerger into Three Focused Entities
The NCLT-approved demerger became effective September 1, 2026, with a record date of September 2, 2026.
Shareholders receive a 1:1 ratio for IGL Spirits and 1:3 for Ennature Bio Pharma.
Reader Takeaway: Sharper business focus and specialized leadership for each entity, balanced by the pending listing timeline uncertainties.
What just happened
India Glycols Limited has officially finalized its corporate restructuring following the receipt of an NCLT Allahabad Bench sanction. The company has filed the necessary documentation with the Registrar of Companies in Uttarakhand. The business has now transitioned into three independent, specialized corporate entities, ending their status as subsidiaries of the original firm.
Key Terms and Share Entitlement
As of the September 2, 2026, record date, the entitlement framework for shareholders is as follows:
- IGL Spirits Limited: 1 equity share for every 1 share held in India Glycols.
- Ennature Bio Pharma Limited: 1 equity share for every 3 shares held in India Glycols.
For instance, a holder of 300 India Glycols shares will now hold 300 shares of IGL Spirits and 100 shares of Ennature Bio Pharma, alongside their original stake.
Business Segments Post-Demerger
- India Glycols Limited: Concentrates on chemicals, glycols, bio-glycols, and industrial gases. It remains listed on the BSE and NSE.
- IGL Spirits Limited: Focuses on IMFL, country liquor, and bio-fuel operations.
- Ennature Bio Pharma Limited: Manages the bio-pharma and bio-polymers portfolio.
Strategic Rationale
The management maintains that separating these units into independent entities will foster improved operational oversight and allow for more efficient resource allocation. By tailoring capital and management strategies to the distinct needs of the chemical, spirit, and bio-pharma sectors, the company aims to unlock long-term value for investors.
What to track next
The immediate focus for shareholders is the forthcoming listing of IGL Spirits Limited and Ennature Bio Pharma Limited on the BSE and NSE. Investors should keep a close watch on future exchange filings for the specific listing timelines for these new entities.